US Retinal Detachment treatment Market

ID: MRFR/Pharma/18484-HCR
100 Pages
Nidhi Mandole
Last Updated: April 06, 2026
US Retinal Detachment Treatment Market Research Report By Condition Type (Rhegmatogenous retinal detachment, Tractional retinal detachment, Exudative retinal detachment), By Treatment (Photocoagulation (Laser surgery), Cryopexy (freezing), Pneumatic retinopexy, Scleral buckling, Vitrectomy) and By End-User (Hospitals, Clinics, Specialty centers, Others) - Growth & Industry Forecast 2025 To 2035
US Retinal Detachment treatment Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)6.9%
2024 Market Size$ 548.1 Million
2025 Market Size$ 589.89 Million
2035 Market Size$ 1,142.4 Million
Key Players
Alcon
Bausch Health Companies
Carl Zeiss AG
CooperVision
Genentech
Johnson & Johnson
Trends
  • Advancements in Surgical Techniques
  • Increased Focus on Early Diagnosis
  • Integration of Telemedicine
Opportunities
  • Growing Geriatric Population
  • Increased Awareness and Education
  • Rising Incidence of Retinal Detachment
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Healthcare, BY Treatment Type (USD Million)
      1. 4.1.1 Surgery
      2. 4.1.2 Laser Therapy
      3. 4.1.3 Pharmacological Treatment
      4. 4.1.4 Cryotherapy
    2. 4.2 Healthcare, BY Patient Demographics (USD Million)
      1. 4.2.1 Age Group
      2. 4.2.2 Gender
      3. 4.2.3 Socioeconomic Status
      4. 4.2.4 Comorbidities
    3. 4.3 Healthcare, BY Diagnosis Method (USD Million)
      1. 4.3.1 Ophthalmic Examination
      2. 4.3.2 Ultrasound Imaging
      3. 4.3.3 Optical Coherence Tomography
      4. 4.3.4 Fundus Photography
    4. 4.4 Healthcare, BY Severity of Condition (USD Million)
      1. 4.4.1 Early Stage
      2. 4.4.2 Moderate Stage
      3. 4.4.3 Advanced Stage
      4. 4.4.4 Recurrent Detachment
    5. 4.5 Healthcare, BY Healthcare Setting (USD Million)
      1. 4.5.1 Hospital
      2. 4.5.2 Outpatient Clinic
      3. 4.5.3 Specialized Eye Care Center
      4. 4.5.4 Emergency Department
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Healthcare
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Alcon (CH)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Bausch Health Companies (CA)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Carl Zeiss AG (DE)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 CooperVision (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Genentech (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Johnson & Johnson (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Novartis (CH)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Regeneron Pharmaceuticals (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Santen Pharmaceutical (JP)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
      10. 5.2.10 Synergetics USA (US)
        1. 5.2.10.1 Financial Overview
        2. 5.2.10.2 Products Offered
        3. 5.2.10.3 Key Developments
        4. 5.2.10.4 SWOT Analysis
        5. 5.2.10.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 US MARKET ANALYSIS BY TREATMENT TYPE
    3. 6.3 US MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    4. 6.4 US MARKET ANALYSIS BY DIAGNOSIS METHOD
    5. 6.5 US MARKET ANALYSIS BY SEVERITY OF CONDITION
    6. 6.6 US MARKET ANALYSIS BY HEALTHCARE SETTING
    7. 6.7 KEY BUYING CRITERIA OF HEALTHCARE
    8. 6.8 RESEARCH PROCESS OF MRFR
    9. 6.9 DRO ANALYSIS OF HEALTHCARE
    10. 6.10 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    11. 6.11 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    12. 6.12 SUPPLY / VALUE CHAIN: HEALTHCARE
    13. 6.13 HEALTHCARE, BY TREATMENT TYPE, 2024 (% SHARE)
    14. 6.14 HEALTHCARE, BY TREATMENT TYPE, 2024 TO 2035 (USD Million)
    15. 6.15 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 (% SHARE)
    16. 6.16 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 TO 2035 (USD Million)
    17. 6.17 HEALTHCARE, BY DIAGNOSIS METHOD, 2024 (% SHARE)
    18. 6.18 HEALTHCARE, BY DIAGNOSIS METHOD, 2024 TO 2035 (USD Million)
    19. 6.19 HEALTHCARE, BY SEVERITY OF CONDITION, 2024 (% SHARE)
    20. 6.20 HEALTHCARE, BY SEVERITY OF CONDITION, 2024 TO 2035 (USD Million)
    21. 6.21 HEALTHCARE, BY HEALTHCARE SETTING, 2024 (% SHARE)
    22. 6.22 HEALTHCARE, BY HEALTHCARE SETTING, 2024 TO 2035 (USD Million)
    23. 6.23 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY TREATMENT TYPE, 2026-2035 (USD Million)
      2. 7.2.2 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million)
      3. 7.2.3 BY DIAGNOSIS METHOD, 2026-2035 (USD Million)
      4. 7.2.4 BY SEVERITY OF CONDITION, 2026-2035 (USD Million)
      5. 7.2.5 BY HEALTHCARE SETTING, 2026-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

US Retinal Detachment treatment Market Segmentation

US Retinal Detachment treatment Market By Treatment Type (USD Million, 2026-2035)

  • Surgery
  • Laser Therapy
  • Pharmacological Treatment
  • Cryotherapy

US Retinal Detachment treatment Market By Patient Demographics (USD Million, 2026-2035)

  • Age Group
  • Gender
  • Socioeconomic Status
  • Comorbidities

US Retinal Detachment treatment Market By Diagnosis Method (USD Million, 2026-2035)

  • Ophthalmic Examination
  • Ultrasound Imaging
  • Optical Coherence Tomography
  • Fundus Photography

US Retinal Detachment treatment Market By Severity of Condition (USD Million, 2026-2035)

  • Early Stage
  • Moderate Stage
  • Advanced Stage
  • Recurrent Detachment

US Retinal Detachment treatment Market By US Retinal Detachment treatment Market Setting (USD Million, 2026-2035)

  • Hospital
  • Outpatient Clinic
  • Specialized Eye Care Center
  • Emergency Department

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.